{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:43:39Z","timestamp":1777877019101,"version":"3.51.4"},"reference-count":45,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tofacitinib is a Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and has been investigated for psoriasis (PsO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This post hoc analysis examined baseline cardiovascular (CV) disease risk and its association with the occurrence of major adverse cardiovascular events (MACE) and malignancies in tofacitinib-treated patients with PsA and PsO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Included three phase III\/long-term extension (LTE) PsA trials and seven phase II\/phase III\/LTE PsO trials of patients receiving\u2009\u2a7e\u20091 dose of tofacitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Incidence rates (IRs: patients with events\/100\u2009patient-years) for MACE and malignancies (excluding non-melanoma skin cancer) were determined in subgroups according to history of atherosclerotic CV disease (ASCVD), baseline 10-year risk of ASCVD (in patients without history of ASCVD), and baseline metabolic syndrome (MetS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>For patients with PsA ( N\u2009=\u2009783) and PsO ( N\u2009=\u20093663), respectively, tofacitinib exposure was 2038 and 8950 patient-years (median duration: 3.0 and 2.4\u2009years), and 40.9% and 32.7% had MetS. Excluding missing CV risk profile data, 51\/773 (6.6%) and 144\/3629 (4.0%) patients had history of ASCVD, and in patients without history of ASCVD, around 20.0% had intermediate\/high baseline 10-year ASCVD risk. For PsA and PsO, IRs of MACE were greatest in those with history of ASCVD or high baseline 10-year ASCVD risk. For PsA, five of six patients with MACE had baseline MetS. Malignancy IRs in patients with PsA were greatest in those with intermediate\/high baseline 10-year ASCVD risk. Of these, eight of nine patients with malignancies had baseline MetS. In the PsO cohort, IR of malignancies was notably greater with high versus low\/borderline\/intermediate baseline 10-year ASCVD risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In tofacitinib-treated patients with PsA\/PsO, increased ASCVD risk and baseline MetS were associated with higher IRs for MACE and malignancies. Our results support assessing CV risk in patients with PsA\/PsO and suggest enhanced cancer monitoring in those with increased ASCVD risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration (ClinicalTrials.gov):<\/jats:title>\n                    <jats:p>NCT01877668\/NCT01882439\/NCT01976364\/NCT00678210\/NCT01710046\/NCT01241591\/NCT01186744\/NCT01276639\/NCT01309737\/NCT01163253<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain Language Summary<\/jats:title>\n                    <jats:p>People who have psoriatic arthritis or psoriasis may have more heart-related problems and cancer if they have a higher risk of cardiovascular disease: A study in people with psoriatic arthritis or psoriasis receiving tofacitinib Why was this study done? \u2022\u2003People with psoriatic arthritis (PsA) and psoriasis (PsO) are more likely than the general population to have a disease affecting the heart and blood vessels [cardiovascular (CV) disease]. \u2022\u2003People who are more likely to have CV disease may also be more likely to have certain types of cancer. \u2022\u2003Tofacitinib is a medicine to treat people with PsA and has been tested in people with PsO. \u2022\u2003We wanted to know if the risk of CV disease affects the number of heart-related problems (including heart attack, stroke, or death) and cancer in people with PsA and PsO. What did the researchers do? \u2022\u2003We used results from 10 clinical trials. \u2022\u2003In these trials, people with PsA and PsO were taking tofacitinib 5 or 10\u2009mg twice a day. \u2022\u2003After the trials had ended, we measured people\u2019s risk of CV disease using a risk calculator. This risk calculator showed if they had a low, borderline, intermediate, or high risk of CV disease over the next 10 years. We also checked if they had had CV disease before treatment. \u2022\u2003We checked if people had a group of conditions linked to CV disease: diabetes, high blood pressure, and obesity. \u2022\u2003We counted the cases of heart-related problems and cancer in people once they started taking tofacitinib. What did the researchers find? In people with PsA and PsO taking tofacitinib: \u2022\u2003There were more cases of heart-related problems and cancer in people who had intermediate or high risk of CV disease. \u2022\u2003There were more cases of heart-related problems in people who had had CV disease before. \u2022\u2003More people with diabetes, high blood pressure, and obesity had heart-related problems and cancer than people without those conditions. What do the findings mean? \u2022\u2003It is important to measure risk and assess history of CV disease in people with PsA and PsO, including those taking tofacitinib. \u2022\u2003We should test for cancer in people with high risk of CV disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1759720x221149965","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T07:05:07Z","timestamp":1675753507000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib"],"prefix":"10.1177","volume":"15","author":[{"given":"Lars E.","family":"Kristensen","sequence":"first","affiliation":[{"name":"The Parker Institute, Bispebjerg and Frederiksberg, Copenhagen, and Copenhagen University, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[{"name":"Central Connecticut Dermatology Research, Cromwell, CT, USA"},{"name":"Yale University, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-6015","authenticated-orcid":false,"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Rheumatology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Epidemiology, German Rheumatism Research Center Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8492-6342","authenticated-orcid":false,"given":"Ying-Ying","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Singapore General Hospital, Singapore"},{"name":"Duke-NUS Medical School, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyejin","family":"Jo","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7475-3369","authenticated-orcid":false,"given":"Kenneth","family":"Kwok","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Vranic","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Tadworth Surrey, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dona L.","family":"Fleishaker","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Fallon","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Montreal, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Yndestad","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Drammensveien 288, 0283 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[{"name":"Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"bibr1-1759720X221149965","first-page":"7","volume":"6","author":"Ayala-Font\u00e1nez N","year":"2016","journal-title":"Psoriasis"},{"key":"bibr2-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.023"},{"key":"bibr3-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"bibr4-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-65"},{"key":"bibr5-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"bibr6-1759720X221149965","volume":"64","author":"Gladman DD","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"bibr7-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X21998279"},{"key":"bibr8-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.02.009"},{"key":"bibr9-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210579"},{"key":"bibr10-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20976975"},{"key":"bibr11-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0024"},{"key":"bibr12-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.12.008"},{"key":"bibr13-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035516"},{"key":"bibr14-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.12.003"},{"key":"bibr15-1759720X221149965","unstructured":"US Food and Drug Administration. XELJANZ\u00ae (tofacitinib) highlights of prescribing information, http:\/\/labeling.pfizer.com\/showlabeling.aspx?id=959 (2021, accessed 14 February 2022)."},{"key":"bibr16-1759720X221149965","unstructured":"European Medicines Agency. Tofacitinib (Xeljanz): summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/referral\/xeljanz-article-20-procedure-annex-iii_en.pdf (2019, accessed 14 February 2022)."},{"key":"bibr17-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"bibr18-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"bibr19-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00010-2"},{"key":"bibr20-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x"},{"key":"bibr21-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1318"},{"key":"bibr22-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9"},{"key":"bibr23-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13551"},{"key":"bibr24-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"bibr25-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.013"},{"key":"bibr26-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16798"},{"key":"bibr27-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"bibr28-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259"},{"key":"bibr29-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.005"},{"key":"bibr30-1759720X221149965","volume":"140","author":"Arnett DK","year":"2019","journal-title":"Circulation"},{"key":"bibr31-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.169404"},{"key":"bibr32-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1016\/0010-4825(92)90023-G"},{"key":"bibr33-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001595"},{"key":"bibr34-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000942"},{"key":"bibr35-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.563"},{"key":"bibr36-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa189"},{"key":"bibr37-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00410-z"},{"key":"bibr38-1759720X221149965","first-page":"1441","volume":"13","author":"Gottlieb AB","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"bibr39-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205675"},{"key":"bibr40-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206617"},{"key":"bibr41-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.058"},{"key":"bibr42-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209775"},{"key":"bibr43-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01145-8"},{"key":"bibr44-1759720X221149965","volume":"16","author":"Zhang X","year":"2021","journal-title":"PLoS ONE"},{"key":"bibr45-1759720X221149965","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2021.100212"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X221149965","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X221149965","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X221149965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:39:03Z","timestamp":1777588743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X221149965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":45,"alternative-id":["10.1177\/1759720X221149965"],"URL":"https:\/\/doi.org\/10.1177\/1759720x221149965","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"1759720X221149965"}}